Axa’s ImmunityBio IBRX Stock Holding History

Axa’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,500	Closed	-$100K	–	1210
2021 Q4	$100K	Sell	16,500 -12,300	-43%	-$92.4K	﹤0.01%	1141
2021 Q3	$281K	Buy	+28,800	New	+$317K	﹤0.01%	1148

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa's IBRX Position: Q1 2022 in Review

Axa sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 16,500 shares — an estimated $100K sold.

Axa first reported a position in IBRX in Q3 2021 and held it in 2 quarters. The position peaked at $281K in Q3 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

Axa reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
Axa sold 16,500 ImmunityBio shares in Q1 2022, an estimated $100K.
Axa first reported a position in ImmunityBio in Q3 2021 and held it in 2 quarters.
Axa's ImmunityBio position peaked at $281K in Q3 2021.
149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Axa's 13F filing for Q1 2022, filed 13 May 2022.